{"title":"Cell death-related signature genes: risk-predictive biomarkers and potential therapeutic targets in severe sepsis.","authors":"Yanan Li, Yuqiu Tan, Zengwen Ma, Weiwei Qian","doi":"10.3389/fmed.2025.1577203","DOIUrl":null,"url":null,"abstract":"<p><p>Sepsis is a systemic inflammatory response syndrome that predisposes to severe lung infections (SeALAR) such as sepsis-associated acute lung injury (Se/ALI) or sepsis-associated acute respiratory distress syndrome (Se/ARDS). Through a systematic bioinformatics approach, this study aimed to unravel the pathogenesis of SeALAR and explore potential biomarkers and individualized therapeutic targets. We analyzed differential genes in the peripheral blood of SeALAR patients based on the GSE10474 and GSE32707 datasets, and identified 352 significantly differentially expressed genes. Various signaling pathways related to immune regulation were found to be significantly altered via GO and KEGG enrichment analysis. Further combining cell death-related gene screening and four machine learning algorithms (including LASSO-logistic, Gradient Boosting Machine, Random Forest and xGBoost), nine SeALAR-characterized cell death genes (SeDGs) were screened and a risk prediction model based on SeDGs was constructed that demonstrated good prediction performance. In immunoassays, ssGSEA showed that Activated.CD8.T.cell, CD56bright.natural.killer.cell, MDSC, Natural.killer.T.cell, T.follicular.helper. cell and TType.1.T.helper.cell had significantly lower infiltration abundance than lower infiltration levels compared to the Se group. GSEA analysis revealed key immune pathways in which SeDGs may be involved. In addition, unsupervised clustering analysis revealed that SeALAR patients could be classified into two molecular subtypes, providing a new direction for the development of individualized immunotherapy strategies. In conclusion, this study systematically analyzed the molecular features and immune disorder mechanism of SeALAR from a multidimensional perspective, and thus provides a theoretical basis and potential targets for precision medicine intervention and targeted drug development.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1577203"},"PeriodicalIF":3.1000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12163320/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1577203","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Sepsis is a systemic inflammatory response syndrome that predisposes to severe lung infections (SeALAR) such as sepsis-associated acute lung injury (Se/ALI) or sepsis-associated acute respiratory distress syndrome (Se/ARDS). Through a systematic bioinformatics approach, this study aimed to unravel the pathogenesis of SeALAR and explore potential biomarkers and individualized therapeutic targets. We analyzed differential genes in the peripheral blood of SeALAR patients based on the GSE10474 and GSE32707 datasets, and identified 352 significantly differentially expressed genes. Various signaling pathways related to immune regulation were found to be significantly altered via GO and KEGG enrichment analysis. Further combining cell death-related gene screening and four machine learning algorithms (including LASSO-logistic, Gradient Boosting Machine, Random Forest and xGBoost), nine SeALAR-characterized cell death genes (SeDGs) were screened and a risk prediction model based on SeDGs was constructed that demonstrated good prediction performance. In immunoassays, ssGSEA showed that Activated.CD8.T.cell, CD56bright.natural.killer.cell, MDSC, Natural.killer.T.cell, T.follicular.helper. cell and TType.1.T.helper.cell had significantly lower infiltration abundance than lower infiltration levels compared to the Se group. GSEA analysis revealed key immune pathways in which SeDGs may be involved. In addition, unsupervised clustering analysis revealed that SeALAR patients could be classified into two molecular subtypes, providing a new direction for the development of individualized immunotherapy strategies. In conclusion, this study systematically analyzed the molecular features and immune disorder mechanism of SeALAR from a multidimensional perspective, and thus provides a theoretical basis and potential targets for precision medicine intervention and targeted drug development.
期刊介绍:
Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate
- the use of patient-reported outcomes under real world conditions
- the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines
- the scientific bases for guidelines and decisions from regulatory authorities
- access to medicinal products and medical devices worldwide
- addressing the grand health challenges around the world